Real World Comparison of Asciminib Versus Ponatinib in Chronic Myeloid Leukemia with Propensity Score-Matched Analysis

Chronic myeloid leukemia (CML) has an excellent prognosis with tyrosine kinase inhibitors (TKIs); however, approximately 40-50% of patients discontinue at least one TKI because of resistance or intolerance. While Ponatinib (PON) is highly effective against resistant disease, Asciminib (ASC) offers robust efficacy with favorable tolerability profile. In the absence of randomized head-to-head trials, we compared outcomes of ASC versus PON using propensity score-matched (PSM) analysis. We conducted a real-world analysis of 762 CML patients previously treated with ≥1 TKI (ASC, n=451; PON, n=311), from an international multicenter cohort. PSM generated 139 balanced pairs after adjusting for age, prior TKI exposure, cardiovascular history, ABL kinase domain mutations, and reason for prior TKI failure. The primary endpoints, evaluated in the matched cohort, were 12-month failure-free survival (FFS) and event-free survival (EFS). ASC was associated with similar molecular response rates and FFS to PON, while EFS was significantly longer with ASC, likely reflecting its more favorable tolerability and lower rate of discontinuation due to intolerance. The difference in EFS was particularly pronounced among patients treated for prior TKI intolerance and in lower-risk subgroups. A sensitivity analysis restricted to patients naïve to both agents (117 matched pairs) confirmed the EFS difference (12-month EFS, 88.6% vs 73.2%; HR 2.48; p=0.002). ASC was associated with similar molecular response and FFS outcomes to PON These findings suggest that ASC was associated with similar real-world molecular response and FFS outcomes to PON, while EFS was longer with ASC, largely driven by differences in treatment discontinuation related to intolerance. ASC may represent an attractive option for patients with prior TKI intolerance, while PON remains an important treatment option for patients with resistant disease.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-18
DOI
https://doi.org/10.1182/bloodadvances.2026021475
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real World Comparison of Asciminib Versus Ponatinib in Chronic Myeloid Leukemia with Propensity Score-Matched Analysis

Swe Mar Linn, Hana Klamová, Simone Claudiani, Peter E. Westerweel et al.
2 links
Blood Advances
Chronic Myeloid Leukemia Treatments
article

Real World Comparison of Asciminib Versus Ponatinib in Chronic Myeloid Leukemia with Propensity Score-Matched Analysis

Swe Mar Linn, Hana Klamová, Simone Claudiani, Peter E. Westerweel, Gopila Gupta, Christophe Bouvier, Shinya H Kimura, Petra Čičátková, Andrew J. Innes, Fausto Castagnetti, Valentín García‐Gutiérrez, Hassan Abdulmaoula Sibai, Julien Bollard, Emilia Scalzulli, Delphine Réa, Camille C.B. Kockerols, María Agustina Perusini, Mary Lynn Savoie, Daniela Žáčková, Jane F. Apperley, Hiroshi Ureshino, Tomoiku Takaku, Sung‐Eun Lee, Dennis Dong Hwan Kim, Dragana Milojković, Massimo Breccia, Carmen Fava, Carolina Pavlovsky, Franck E. Nicolini, Jiří Mayer
article en

Abstract

Chronic myeloid leukemia (CML) has an excellent prognosis with tyrosine kinase inhibitors (TKIs); however, approximately 40-50% of patients discontinue at least one TKI because of resistance or intolerance. While Ponatinib (PON) is highly effective against resistant disease, Asciminib (ASC) offers robust efficacy with favorable tolerability profile. In the absence of randomized head-to-head trials, we compared outcomes of ASC versus PON using propensity score-matched (PSM) analysis. We conducted a real-world analysis of 762 CML patients previously treated with ≥1 TKI (ASC, n=451; PON, n=311), from an international multicenter cohort. PSM generated 139 balanced pairs after adjusting for age, prior TKI exposure, cardiovascular history, ABL kinase domain mutations, and reason for prior TKI failure. The primary endpoints, evaluated in the matched cohort, were 12-month failure-free survival (FFS) and event-free survival (EFS). ASC was associated with similar molecular response rates and FFS to PON, while EFS was significantly longer with ASC, likely reflecting its more favorable tolerability and lower rate of discontinuation due to intolerance. The difference in EFS was particularly pronounced among patients treated for prior TKI intolerance and in lower-risk subgroups. A sensitivity analysis restricted to patients naïve to both agents (117 matched pairs) confirmed the EFS difference (12-month EFS, 88.6% vs 73.2%; HR 2.48; p=0.002). ASC was associated with similar molecular response and FFS outcomes to PON These findings suggest that ASC was associated with similar real-world molecular response and FFS outcomes to PON, while EFS was longer with ASC, largely driven by differences in treatment discontinuation related to intolerance. ASC may represent an attractive option for patients with prior TKI intolerance, while PON remains an important treatment option for patients with resistant disease.

Blood Advances
Hiroshima University (JP), Imperial College Healthcare NHS Trust (GB), Inserm (FR), University of Calgary (CA), Saga University (JP), University of Toronto (CA), Hammersmith Hospital (GB), Erasmus MC (NL), Princess Margaret Cancer Centre (CA), Albert Schweitzer Ziekenhuis (NL), Institute of Haematology and Blood Transfusion (CZ), Assistance Publique – Hôpitaux de Paris (FR), University Hospital Brno (CZ), Centre Léon Bérard (FR), Alberta Cancer Foundation (CA), Centre de Recherche en Cancérologie de Lyon (FR), Fundación para la Investigación, Docencia y Prevención del Cáncer (AR), Hôpital Saint-Louis (FR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Hospital Universitario Ramón y Cajal (ES), Arthur J.E. Child Comprehensive Cancer Centre (CA), Imperial College London (GB), University of Turin (IT), Saitama Medical University (JP), Sapienza University of Rome (IT), Catholic University of Korea (KR), University of Bologna (IT)
Good health and well-being
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon